Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Asahi Kasei
Thumbnail
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Thumbnail
September 14, 2021

No sleepless nights for Asahi Kasei over $538m Itamar deal

Article image
Vantage logo
March 11, 2020

Tiziana takes a deep breath and targets Covid-19

Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?

Article image
Vantage logo
November 14, 2019

Medtech venture investors wait for an exit

The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.

Article image
Vantage logo
October 24, 2019

Diagnostics specialists win the US device approval race

The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.

Article image
Vantage logo
January 31, 2019

In sticking to the knitting has Array given up too much?

At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.

Article image
Vantage logo
May 21, 2018

Boston Scientific’s plan to keep the rhythm going

An acquisitive company has a plan for the future.

Vantage logo
March 10, 2017

Snippet roundup: Acorda wins, Ionis loses – maybe

Vantage logo
March 12, 2015

Big in Japan? As drug costs surge, diabetes and cancer win healthy premiums

Vantage logo
March 11, 2015

Biennial drug price cuts show no sign of holding back the Japanese market

Vantage logo
July 25, 2013

Medtech M&A on course for the worst year in a decade

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

August 15, 2022

Q2 Roundp Medtech Infographic

August 12, 2022

Q2 Roundup Pharma Infographic

View more...

Editor's Picks

Vantage logo
July 27, 2022

Aids 2022 preview – Gilead shoots for an HIV cure

Vantage logo
July 21, 2022

Private equity gets serious about drug development

Vantage logo
July 18, 2022

Unpacking Royalty Pharma

Vantage logo
July 19, 2022

No plain sailing for Novartis’s PD-1 plan

Vantage logo
July 26, 2022

Move over Aduhelm, it’s tofersen’s turn

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.

Open modal